RT Book, Section A1 Hill, Samuel L. A1 Johnson, Peter W.M. A2 Board, Ruth E. A2 Nathan, Paul A2 Newsom-Davis, Tom A2 Papa, Sophie A2 Johnson, Peter SR Print(0) ID 1160632587 T1 Immunotherapy: Past, Present and Future T2 Problem Solving in Cancer Immunotherapy YR 2019 FD 2019 PB EBN Health PP New York, NY SN 9780995595422 LK hemonc.mhmedical.com/content.aspx?aid=1160632587 RD 2021/01/27 AB The intuitive appeal of eliciting an effective immune response against cancers has long been recognized but, until quite recently, rarely fulfilled. At the end of the 19th century, William Coley, a New York sarcoma surgeon, noted some tumour regressions in cancer patients infected with streptococci, by provoking an immune response.1 But such responses proved hard to replicate and his treatments quickly fell out of favour. The idea, however, remained potent. Occasional instances of spontaneous tumour regression2,3 or prolonged dormancy suggested some form of ‘host restraint’, and a number of clinical successes kept the field of immunotherapy alive, despite the many failed attempts at treatment.